grant
A translational study of a synthetic lethality interaction of CD105 and androgen receptor signaling axis for castration-resistant prostate cancer patients
Organization CEDARS-SINAI MEDICAL CENTERLocation LOS ANGELES, UNITED STATESPosted 1 Jul 2024Deadline 30 Jun 2029
NIHUS FederalResearch GrantFY2025AccountingAffectAfter CareAfter-TreatmentAftercareAmerican maleAmerican manAmerican menAndrogen ReceptorAndrogenic AgentsAndrogenic CompoundsAndrogensAppearanceBehaviorBiochemicalBiologyBloodBlood Reticuloendothelial SystemBone MarrowBone Marrow Reticuloendothelial SystemBone Morphogenetic Protein GeneBone Morphogenetic ProteinsBone-Derived Transforming Growth FactorCD105CD105 GeneCEK2Cancer CauseCancer EtiologyCancer PatientCancersCarcinomaCell BodyCell Communication and SignalingCell NucleusCell SignalingCellsCellular MorphologyCessation of lifeClinicalCombined Modality TherapyDNA Synthesis FactorDeathDevelopmentDisease ProgressionDisease ResistanceEND GeneENG geneEndoglin GeneEndothelial Cell Growth FactorEpithelial cancerEpitheliumEpithelium of Human Prostate GlandFGFFGF ReceptorsFGF-RFGF8FGF8 geneFGFRFGFR-3FGFR3FGFR3 geneFibroblast Growth FactorFibroblast Growth Factor Gene FamilyFibroblast Growth Factor Receptor FamilyFibroblast Growth Factor ReceptorsFibroblast Growth Regulatory FactorFibroblastsFrequenciesGene ExpressionGenomicsGlnGlutamineGoalsHBGF-8HHT1HHT1 GeneHSFGFR3EXInterruptionInterventionIntracellular Communication and SignalingJTK4L-GlutamineMalignant Epithelial NeoplasmsMalignant Epithelial TumorsMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMediatorMiceMice MammalsMilk Growth FactorModificationMolecular AnalysisMonitorMorphologyMultimodal TherapyMultimodal TreatmentMurineMusNanoVelcroNanoplatformNanotechnological platformNanotechnologyNeoplasm Circulating CellsNeuroendocrine CellNucleusORW GeneORW1ORW1 GenePDX modelParacrine CommunicationParacrine SignalingPatient SelectionPatient derived xenograftPatientsPharmacodynamicsPlatelet Transforming Growth FactorPre-Clinical ModelPreclinical ModelsPredictive ValuePrognosisProstateProstate CAProstate CancerProstate GlandProstate malignancyProstatic EpitheliumProstatic GlandQ LevoglutamideQ. LevoglutamideQOLQuality of lifeRNA SplicingRadiographyRandomizedReceptor InhibitionReceptor SignalingReportingResistanceResistance developmentResistant developmentRoentgenographyRoleSamplingSelection CriteriaSignal TransductionSignal Transduction SystemsSignalingSignaling Factor Proto-OncogeneSignaling Pathway GeneSignaling ProteinSplicingSystemTGF BTGF-betaTGF-beta ReceptorsTGF-βTGF-β ReceptorsTGFbetaTGFβTechnologyTestingTherapeutic AndrogenTransforming Growth Factor betaTransforming Growth Factor beta ReceptorsTransforming Growth Factor β ReceptorsTransforming Growth Factor-Beta Family GeneTumor CellTumor ExpansionTyrosine Kinase JTK4U.S. MalesUS MenUS maleUpregulationVariantVariationXtandiabirateroneadvanced prostate canceralternative treatmentandrogen independent prostate cancerandrogen indifferent prostate cancerandrogen insensitive prostate cancerandrogen resistance in prostate cancerandrogen resistant prostate cancerantagonismantagonistbiological signal transductionbone morphogenic proteincancer microenvironmentcancer progressioncastration resistant CaPcastration resistant PCacastration resistant prostate cancercell morphologycirculating neoplastic cellcirculating tumor cellclinical developmentcombination therapycombined modality treatmentcombined treatmentdeveloping resistancedevelopmentaldisease controldisorder controlenzalutamideepithelial carcinomaexperimentexperimental researchexperimental studyexperimentsfibroblast growth factor receptor 3gene signaturesgenetic signaturegenome profilinggenomic profilinghFGFR3hormone refractory prostate cancerimprovedinhibitorinhibitor druginhibitor therapeuticinhibitor therapyinnovateinnovationinnovativeinsightmales in Americamales in the U.S.males in the USmales in the USAmales in the United Statesmalignancymenmen in Americamen in the U.S.men in the USmen in the USAmen in the United Statesmortalitymulti-modal therapymulti-modal treatmentnano technano technologynano-technologicalnanotechnanotechnologicalnanotechnology platformneoplasm progressionneoplasm/cancerneoplastic cellneoplastic progressionneuroendocrine phenotypeneutralizing antibodynext generationnovelparacrinepatient derived xenograft modelphase 2 studyphase 2 trialphase II studyphase II trialpost treatmentpreventpreventingprimary end pointprimary endpointprognostic abilityprognostic powerprognostic utilityprognostic valueprogramsprospectiveprostate cancer cellprostate cancer resistant to androgenprostate tumor cellradiological imagingrandomisationrandomizationrandomized, clinical trialsrandomly assignedresistance mechanismresistance to diseaseresistance to therapyresistantresistant diseaseresistant mechanismresistant to diseaseresistant to therapyresponseresponse to therapyresponse to treatmentserum PSAserum prostate specific antigensocial rolesynthetic lethal interactionsynthetic lethalitytargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic agent developmenttherapeutic developmenttherapeutic resistancetherapeutic responsetherapy resistanttherapy responsetranslation strategytranslational approachtranslational strategytranslational studytreatment resistancetreatment responsetreatment responsivenesstumortumor microenvironmenttumor progressiontumorigenic
Get Agency plan to apply$29.99/mo · 7-day free trial · pipeline · alerts
or
— or —Get email alerts for similar roles
Description preview
The goal of this proposal is to better understand a novel signaling axis initiated in prostate cancer (PCa)
patients by next-generation androgen receptor signaling inhibitors (ARSIs). The standard use of ARSIs in PCa
patients help limit tumor progression, but inevitably result in the development of therapeutically resistant
disease. We have…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click